Research & Development
Eiger BioPharmaceuticals' David Apelian to step down
20 May 2019 -

Eiger BioPharmaceuticals Inc (Nasdaq: EIGR), a US-based company focused on the development and commercialisation of targeted therapies for serious rare and ultra-rare diseases, announced on Friday that David Apelian will step down as the company's chief operating officer and executive medical officer, effective 14 June 2019.

Dr Apelian is to become the chief executive officer at a private biotech company. He will remain actively engaged with Eiger and will continue to serve on Eiger's board of directors. Dr Apelian will consult with the company to assist with the transition.

David Cory, chief executive officer at Eiger, said, 'I want to thank David for his service to Eiger, particularly in leading the Company's hepatitis delta virus (HDV) program. David played an important role in negotiating Phase 3 D-LIVR study design and endpoints with FDA, allowing Eiger to initiate the first-ever Phase 3 study in HDV. David has built a strong clinical team, and Eiger is poised to execute across all programs. I wish him well in his new position and look forward to continuing to work with him on our board.'

Login
Username:

Password: